Mazdutide Shows Promise in Controlling blood sugar and Obesity in Diabetes Patients: Study

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-03-10 14:45 GMT   |   Update On 2024-03-10 14:45 GMT

Mazdutide, a dual agonist drug was found to target weight reduction and additionally to manage blood glucose levels in individuals with overweight and obesity. The key highlights of this study was published in the recent edition of Frontiers in Endocrinology.Amidst the anticipation surrounding the efficacy of Mazdutide, the concerns regarding the scarcity of comprehensive evidence on...

Login or Register to read the full article

Mazdutide, a dual agonist drug was found to target weight reduction and additionally to manage blood glucose levels in individuals with overweight and obesity. The key highlights of this study was published in the recent edition of Frontiers in Endocrinology.

Amidst the anticipation surrounding the efficacy of Mazdutide, the concerns regarding the scarcity of comprehensive evidence on its effectiveness and safety prevailed. To address this, a recent study by David Lubasi Nalisa and coulleagues was conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the impact of Mazdutide on weight reduction among adults with and without diabetes.

Analysis of seven RCTs involving a total of 680 participants revealed the superiority of Mazdutide over placebo in various aspects. The drug showed effectiveness in reducing body weight, systolic and diastolic blood pressure, total cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein.

Mazdutide demonstrated positive effects in the management of hemoglobin A1c (HbA1c) and fasting plasma glucose levels in individuals with type 2 diabetes which underlines its potential as a multifaceted therapeutic approach.

Further analysis through subgroup and meta-regression analyses unveiled nuances, where weight reduction was notable and more significant in non-diabetic individuals when compared to the diabetics, especially among the individuals who were undergoing longer treatment durations (24 weeks).

The outcomes of this study also highlighted a pertinent concern regarding the safety profile of Mazdutide. While the drug expressed promising efficacy, the participants reported transient mild to moderate gastrointestinal side effects which suggests a need for careful monitoring and management strategies.

Reference:

Nalisa, D. L., Cuboia, N., Dyab, E., Jackson, I. L., Felix, H. J., Shoki, P., Mubiana, M., Oyedeji-Amusa, M., Azevedo, L., & Jiang, H. (2024). Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. In Frontiers in Endocrinology (Vol. 15). Frontiers Media SA. https://doi.org/10.3389/fendo.2024.1309118

Tags:    
Article Source : Frontiers in Endocrinology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News